Compound Evidence File
#EC-2026-0787
Anavar (Oxandrolone)
Filed under Oral Tablets. The bureau holds 159 laboratory returns for this compound from 52 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
52 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 10.0 | 9.9 | 10.0 | 4 Nov 2025 | 22 Mar 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 10.0 | 9.9 | 10.0 | 10 Jan 2026 | 9 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 4 | 10.0 | 10.0 | 10.0 | 19 Dec 2025 | 8 Aug 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 9.9 | 10.0 | 15 Dec 2025 | 26 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 9.9 | 10.0 | 5 May 2026 | 24 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 10.0 | 9.9 | 10.0 | 28 Mar 2026 | 14 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 10.0 | 10.0 | 10.0 | 22 Jan 2026 | 6 Apr 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 10.0 | 10.0 | 10.0 | 7 Jan 2026 | 6 Jun 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 10.0 | 10.0 | 10.0 | 25 May 2026 | 19 Jun 2026 |
| Verified PeptidesCASE #VI-2026-0407 | X | 2 | 10.0 | 10.0 | 10.0 | 28 Mar 2025 | 25 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 9.9 | 9.9 | 10.0 | 23 Jan 2026 | 12 Jul 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 9.9 | 9.9 | 10.0 | 21 May 2026 | 21 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 10.0 | 21 Apr 2026 | 16 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 11 Jan 2026 | 15 Jun 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 9.9 | 9.9 | 10.0 | 4 Jun 2026 | 12 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 9.9 | 9.9 | 10.0 | 1 Apr 2026 | 4 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 9.9 | 9.9 | 10.0 | 11 Nov 2025 | 27 Jan 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 9.9 | 9.9 | 10.0 | 28 Apr 2026 | 9 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 9.9 | 9.9 | 10.0 | 23 Feb 2026 | 12 Aug 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 9.9 | 9.9 | 9.9 | 1 Feb 2026 | 21 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 10.0 | 14 May 2026 | 3 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 8 Jun 2026 | 10 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 10.0 | 14 Dec 2025 | 21 May 2026 |
| NextechLabsCASE #VI-2026-0285 | X | 2 | 9.2 | 8.3 | 10.0 | 13 Feb 2025 | 25 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 8.8 | 8.1 | 9.6 | 23 May 2026 | 23 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 2 | 8.8 | 8.7 | 8.8 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 5 | 8.5 | 7.5 | 10.0 | 23 May 2026 | 23 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 6 | 8.4 | 7.3 | 9.5 | 21 May 2026 | 21 May 2026 |
| Reta-PeptideCASE #VI-2026-0756 | X | 13 | 8.2 | 6.6 | 10.0 | 25 Apr 2025 | 20 May 2026 |
| TCICASE #VI-2026-0650 | X | 1 | 8.2 | 8.2 | 8.2 | 13 Feb 2025 | 13 Feb 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 3 | 7.6 | 7.4 | 7.7 | 25 May 2026 | 25 May 2026 |
| OmegAminoCASE #VI-2026-0014 | X | 1 | 7.6 | 7.6 | 7.6 | 6 May 2025 | 6 May 2025 |
| OupeptideCASE #VI-2026-0435 | X | 10 | 7.5 | 5.0 | 10.0 | 16 Mar 2025 | 24 May 2026 |
| Shanghai Leader Peptide BiotechnologyCASE #VI-2026-0558 | X | 1 | 7.5 | 7.5 | 7.5 | 13 Jun 2025 | 13 Jun 2025 |
| AKS ChemCASE #VI-2026-0313 | X | 1 | 7.4 | 7.4 | 7.4 | 9 Jun 2025 | 9 Jun 2025 |
| SRY LabsCASE #VI-2026-0657 | X | 1 | 7.1 | 7.1 | 7.1 | 13 Feb 2025 | 13 Feb 2025 |
| Zhang TYCASE #VI-2026-0070 | X | 1 | 7.1 | 7.1 | 7.1 | 16 Mar 2025 | 16 Mar 2025 |
| Kits4lessCASE #VI-2026-0744 | X | 1 | 7.0 | 7.0 | 7.0 | 14 Jan 2025 | 14 Jan 2025 |
| YimeiCASE #VI-2026-0081 | X | 4 | 6.4 | 5.5 | 8.0 | 11 Jun 2025 | 21 May 2026 |
| Royal PeptidesCASE #VI-2026-0264 | X | 3 | 6.0 | 3.5 | 9.4 | 2 Apr 2025 | 19 Jan 2026 |
| Zztai PeptideCASE #VI-2026-0192 | C | 3 | 5.9 | 5.4 | 6.3 | 7 May 2025 | 17 May 2026 |
| Forever Young PharmacyCASE #VI-2026-0654 | X | 2 | 5.7 | 4.3 | 7.1 | 11 Jun 2025 | 26 Jan 2026 |
| PeptiLab ResearchCASE #VI-2026-0267 | X | 1 | 5.6 | 5.6 | 5.6 | 7 May 2025 | 7 May 2025 |
| Eternal PeptidesCASE #VI-2026-0842 | X | 1 | 5.4 | 5.4 | 5.4 | 17 Dec 2024 | 17 Dec 2024 |
| ZhuoYan labCASE #VI-2026-0902 | X | 3 | 5.1 | 3.2 | 7.0 | 7 May 2025 | 21 May 2026 |
| TydesCASE #VI-2026-0493 | X | 1 | 4.8 | 4.8 | 4.8 | 27 Feb 2025 | 27 Feb 2025 |
| YB PeptideCASE #VI-2026-0813 | X | 1 | 4.7 | 4.7 | 4.7 | 27 Feb 2025 | 27 Feb 2025 |
| DeuschemCASE #VI-2026-0004 | X | 2 | 4.5 | 4.0 | 4.9 | 7 May 2025 | 20 May 2026 |
| Amino AmigosCASE #VI-2026-0061 | X | 2 | 2.0 | 1.6 | 2.5 | 13 Feb 2025 | 24 May 2026 |
| Zhuoyue BiotechnologyCASE #VI-2026-0632 | X | 1 | 1.0 | 1.0 | 1.0 | 17 Dec 2024 | 17 Dec 2024 |
| Advanced Technology and IndustrialCASE #VI-2026-0133 | X | 1 | 0.0 | 0.0 | 0.0 | 14 Jan 2025 | 14 Jan 2025 |
Open any subject to view the batch-level evidence for Anavar (Oxandrolone) alone.